Clinical Trial Update: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder [Phase 1]

View source ↗

Summary

A Phase 1 randomized open-label pharmacokinetic study comparing LY03004 with Risperdal Consta in stable patients with schizophrenia or schizoaffective disorder …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• LY03004
• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1 | Status: COMPLETED